Menu Search
Equities

BioArctic AB

BIOA B:STO

BioArctic AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)189.60
  • Today's Change4.20 / 2.27%
  • Shares traded276.46k
  • 1 Year change-19.66%
  • Beta0.0768
Data delayed at least 15 minutes, as of Nov 22 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year BioArctic AB grew revenues 169.83% from 228.29m to 616.00m while net income improved from a loss of 11.18m to a gain of 229.25m.
Gross margin80.72%
Net profit margin-139.32%
Operating margin-151.43%
Return on assets-19.94%
Return on equity-22.75%
Return on investment-22.13%
More ▼

Cash flow in SEKView more

In 2023, cash reserves at BioArctic AB fell by 193.82m. However, the company earned 309.69m from its operations for a Cash Flow Margin of 50.28%. In addition the company generated 14.06m cash from financing while 507.49m was spent on investing.
Cash flow per share-0.9325
Price/Cash flow per share--
Book value per share10.39
Tangible book value per share10.39
More ▼

Balance sheet in SEKView more

BioArctic AB appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio8.35
Quick ratio--
Total debt/total equity0.0614
Total debt/total capital0.0578
More ▼

Growth rates in SEK

Year on year, growth in earnings per share excluding extraordinary items increased 2,092.89%. Additionally, five year annualized earnings per share growth ranks highest in its industry.
EPS growth(5 years)-9.76
EPS (TTM) vs
TTM 1 year ago		-192.82
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.